在三阴性乳腺癌中,MiR-4646-5p作为瘤抑制因子,向胆固醇运输蛋白GRAMD1B
Katharina Jonas1,2, Felix Prinz1,2, Manuela Ferracin3
1Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Non-coding RNA
|January 22, 2024
概括
像miR-4646-5p这样的microRNAs (miRNAs) 在治疗三阴性乳腺癌 (TNBC) 中表现有前途. 更高的miR-4646-5p水平与更好的TNBC患者存活率相关,并抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因规则 基因规则
背景情况:
- 微RNAs (miRNAs) 是关键的基因调节剂,与癌症发展有关.
- 三阴性乳腺癌 (TNBC) 需要新的治疗策略.
- 在乳腺癌中miR-4646-5p的作用仍然在很大程度上未被描述.
研究的目的:
- 为了研究miR-4646-5p在三阴性乳腺癌中的功能.
- 确定miR-4646-5p表达在TNBC患者中的临床意义.
- 确定分子点和机制,以确定miR-4646-5p在TNBC中的作用.
主要方法:
- 在TNBC患者数据中分析miR-4646-5p表达.
- 在体外功能测定 (细胞生长,增殖,迁移,管形成).
- 整体转录组分析以确定下游目标和途径.
- 直接miRNA-目标相互作用 (GRAMD1B) 的验证.
主要成果:
- 更高的miR-4646-5p表达与TNBC患者的生存率改善有关.
- 过度表达miR-4646-5p抑制了TNBC细胞的生长,增殖和迁移.
- miR-4646-5p通过抑制内皮细胞管形成,证明了抗血管性潜力.
- miR-4646-5p降低瘤原因子的调节,并直接准胆固醇运输蛋白GRAMD1B.
结论:
- miR-4646-5p在三阴性乳腺癌中表现出抑制瘤的特性.
- miR-4646-5p可能作为TNBC的治疗点.
- 在TNBC中,GRAMD1B是miR-4646-5p抗癌作用的潜在调解者.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


